Axsome Therapeutics, Inc.
AXSM
$121.91
$0.260.21%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 118.77M | 104.76M | 87.17M | 75.00M | 71.53M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 118.77M | 104.76M | 87.17M | 75.00M | 71.53M |
| Cost of Revenue | 10.51M | 8.44M | 8.06M | 6.30M | 7.38M |
| Gross Profit | 108.25M | 96.33M | 79.11M | 68.70M | 64.15M |
| SG&A Expenses | 113.27M | 95.56M | 103.55M | 98.97M | 86.81M |
| Depreciation & Amortization | 1.61M | 1.61M | 1.59M | 1.59M | 1.61M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 180.40M | 151.00M | 163.05M | 143.69M | 126.60M |
| Operating Income | -61.63M | -46.23M | -75.89M | -68.69M | -55.07M |
| Income Before Tax | -74.83M | -64.60M | -79.35M | -68.36M | -98.98M |
| Income Tax Expenses | 85.00K | -- | -- | -- | -325.00K |
| Earnings from Continuing Operations | -74.91M | -64.60M | -79.35M | -68.36M | -98.65M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -74.91M | -64.60M | -79.35M | -68.36M | -98.65M |
| EBIT | -61.63M | -46.23M | -75.89M | -68.69M | -55.07M |
| EBITDA | -59.56M | -44.17M | -73.78M | -66.97M | -53.33M |
| EPS Basic | -1.54 | -1.34 | -1.67 | -1.44 | -2.08 |
| Normalized Basic EPS | -0.82 | -0.63 | -1.01 | -0.92 | -0.74 |
| EPS Diluted | -1.54 | -1.34 | -1.67 | -1.44 | -2.08 |
| Normalized Diluted EPS | -0.82 | -0.63 | -1.01 | -0.92 | -0.74 |
| Average Basic Shares Outstanding | 48.54M | 48.14M | 47.57M | 47.39M | 47.33M |
| Average Diluted Shares Outstanding | 48.54M | 48.14M | 47.57M | 47.39M | 47.33M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
